The so-called "holding at the bottom" is generally a means by which listed companies are determined to maintain the stock price for watch protection, which can usually produce good results in a short period of time.

Last night, International Medicine issued an announcement revealing the "bottom-up" initiative of the company's real controllers. Today, the international medical market continued to rise after opening high. as of press time, the share price rose by the limit of 11.03 yuan per share.

On September 16, the international medical announcement, the company received the actual controller Liu Jianshen submitted a "proposal to all employees of the company to increase their holdings of the company's shares."

Liu Jianshen, the controller of the company, promises that, in accordance with the relevant operating rules of this initiative, international medical stocks are bought net through employees' own securities accounts in the form of secondary market bidding between September 17 and October 11, 2021, and employees who have been holding for more than 12 months in a row will lose money as a result of increasing their holdings of international medical stocks during the above-mentioned period. Liu Jianshen or his designated subordinate companies will compensate with their own funds. If there is any stock appreciation income, it will be owned by the employee personally.

As for the reason for the international medical controller's proposal to increase its holdings, it is mainly due to the continuous decline in the stock price of International Medicine in recent months, which has halved in more than three months since it reached an all-time high of 21.66 yuan in June.

At the beginning of this year, the medical beauty track wind blowing, a number of concept stocks ushered in a wave of rise. In the first half of 2021, the share prices of listed companies hit record highs.

On June 2, International Medicine set a five-year high of 21.66 yuan per share in intraday trading, while the company's market capitalization reached about 49.298 billion yuan.

However, the strong rise in international medical stock prices did not last long before entering the downward channel.

Although the stock price once rose by virtue of the concept of medical beauty, the development of international medicine itself continued to lose money.

According to the financial report, in the first half of 2021, International Medical recorded revenue of 1.306 billion yuan, a year-on-year increase of 104.10%, and recorded a net profit loss of 360 million yuan, down 4.60% from the same period last year.

The substantial increase in revenue did not lead to an increase in profits, and the half-year performance forecast shows that the estimated net profit loss of 352 million yuan to 362 million yuan, which is larger than the loss of 344 million yuan in the same period last year.

In fact, institutions have retreated before and after the announcement, which is also the main reason for the collapse of international medical stock prices.

Finally, the rise of the stock price of listed companies must be supported by performance. "increasing holdings at the bottom" and other means can only maintain the stock price for a short time, and listed companies still have to operate well to bring returns to investors.